IDEAYA Biosciences (IDYA) has drawn fresh attention after announcing a clinical collaboration with Genentech on August 19, 2026, focused on IDE892 and GDC-7035 in genetically defined pancreatic ductal adenocarcinoma.

For investors tracking IDEAYA Biosciences, the recent collaboration news comes on top of strong price momentum, with a 90 day share price return of 41.72% and a 1 year total shareholder return of 66.32%, even after a 1 day share price decline of 2.12% to US$41.58.

Spot opportunities beyond IDEAYA Biosciences by scanning our hand picked 20 high quality undiscovered gems, which share strong fundamentals and are still flying under most investors' radar.

After IDEAYA Biosciences rallied on the Genentech collaboration, the share price now sits between recent trading levels and published value estimates. So where does a reasonable fair value range actually land for this stock?

Preferred Price-to-Sales Multiple of 17.1x: Is It Justified?

Simply Wall St currently flags IDEAYA Biosciences as trading at 31.6% below its own estimate of fair value based on future cash flows, yet the market price of $41.58 also reflects a P/S ratio of 17.1x that is higher than several benchmarks. That mix of signals leaves investors weighing a discounted cash flow view against what the sales multiple is implying about expectations.

The P/S ratio compares a company’s market value to its revenue. For a business like IDEAYA Biosciences, which is still unprofitable and reported a loss of $175.02m on revenue of $234.13m, sales-based metrics are often used because earnings do not yet provide a stable reference point. A higher P/S can indicate the market is placing a premium on the company’s current revenue base, potential pipeline, or expected future growth in sales.

In IDEAYA Biosciences' case, the preferred multiple checks say that this 17.1x P/S ratio is expensive compared with the estimated fair P/S ratio of 4.4x, the peer average of 14.1x, and the broader US Biotechs industry average of 13.4x. That is a sizeable gap, and it suggests the current price bakes in stronger expectations than what the regression-based fair ratio implies the market could eventually move toward if sentiment or assumptions normalise.

Explore the SWS fair ratio for IDEAYA Biosciences.

Result: Price-to-sales of 17.1x (OVERVALUED)

However, you still need to consider risks, including IDEAYA Biosciences' ongoing losses and the chance that clinical or partnership setbacks could quickly challenge this pricing story.

Another View On IDEAYA Biosciences Using Our DCF Model

The sales multiple paints IDEAYA Biosciences as expensive, yet the SWS DCF model currently points the other way. At $41.58, the stock is flagged as trading about 31.6% below an estimated future cash flow value of $60.78. That raises an obvious question: Which signal do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out IDEAYA Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals on IDEAYA Biosciences leave you unsure, review the data now and form your own stance while sentiment is still moving. To weigh both sides of the story in one place, start with the 2 key rewards and 1 important warning sign.

Looking For More Investment Ideas Beyond IDEAYA Biosciences?

If IDEAYA Biosciences is on your radar, do not stop there. The same tools that helped assess this stock can surface other potential opportunities worth your attention.

• Broaden your watchlist with companies that combine solid fundamentals and attractive pricing by scanning our hand picked 51 high quality undervalued stocks.
• Strengthen the defensive side of your portfolio by reviewing a curated list of solid balance sheet and fundamentals (51 results).
• Reduce surprises in your holdings by focusing on stability through our 75 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.